Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 20/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 10/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16611452 | 0.80 | PTGS2 (0.43) | PTGS2PTGS1 | |
| SCHEMBL16611316 | 0.74 | CA1 (0.42) | PTGS2PTGS1 | |
| SCHEMBL16611691 | 0.74 | PTGS2 (0.36) | PTGS2PTGS1 | |
| SCHEMBL16611690 | 0.74 | PTGS2 (0.45) | PTGS2PTGS1 | |
| SCHEMBL16611177 | 0.71 | KHK (0.40) | PTGS2 | |
| SCHEMBL31202803 | 0.68 | PTGS2 (0.51) | PTGS2PTGS1CYP2C9 | |
| SCHEMBL26108786 | 0.68 | PTGS2 (0.51) | PTGS2PTGS1CYP2C9 | |
| SCHEMBL5429991 | 0.68 | PTGS2 (0.60) | PTGS2PTGS1CYP2C9 | |
| SCHEMBL16611260 | 0.65 | PTGS2 (0.42) | PTGS2PTGS1CYP2C9 | |
| SCHEMBL31729210 | 0.65 | CCR4 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | PTGS2 550/4885PTGS1 442/4885CYP2C9 3489/4885 |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | PTGS2 550/4885PTGS1 442/4885CYP2C9 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.